title: A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
authors.affiliation: University of Essen, West German Cancer Center, Essen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Richly
authors.forename: P
authors.initials: P
authors.lastname: Kupsch
authors.forename: K
authors.initials: K
authors.lastname: Passage
authors.forename: M
authors.initials: M
authors.lastname: Grubert
authors.forename: R A
authors.initials: RA
authors.lastname: Hilger
authors.forename: S
authors.initials: S
authors.lastname: Kredtke
authors.forename: D
authors.initials: D
authors.lastname: Voliotis
authors.forename: M E
authors.initials: ME
authors.lastname: Scheulen
authors.forename: S
authors.initials: S
authors.lastname: Seeber
authors.forename: D
authors.initials: D
authors.lastname: Strumberg
mesh_terms: D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D001219:Aspartate Aminotransferases / Q000494:pharmacology; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D004317:Doxorubicin; D000077157:Sorafenib; D001219:Aspartate Aminotransferases